Skip to main content
. 2015 Nov 26;7(1):671–683. doi: 10.18632/oncotarget.6400

Figure 2. Anti-tumor effect of HLA-A2-restricted TAL6 peptide immunization in HLA-A2 transgenic mice.

Figure 2

A. HLA-A2 transgenic mice were immunized s.c. twice with peptide A2-5 formulated with the Th epitope peptide in ISA or ISA alone. After the final immunization, splenocytes were harvested from the mice and co-cultured with EL4-TAL6-A2 or EL4-TAL6 cells for 2 hr. The percentage of CD107a+CD8+ cells was detected by flow cytometry. Error bars, SD from three independent experiments; *, P < 0.05; **, P < 0.01. B. At 7 days after final immunization of PBS or peptide A2-5 in HLA-A2 transgenic mice, EL4-TAL6-A2 or EL4-TAL6 cancer cells (2 × 105 cells per mouse) were injected subcutaneously and the tumor growth was monitored. Each group contains 5 mice. Error bars, SEM; **, P < 0.01.